In contrast to the fluctuating global M&A market, the life sciences and health tech industry saw a significant uptick in deal-making throughout 2023, showcasing remarkable resilience and growth.
2.5.2024
Strong momentum in life sciences and health tech industry: Castrén & Snellman sees a significant uptick in deal-making
Karlo Siirala, Hanna Paloheimo, Sakari Lukinmaa, Tero Tuomisto & Antti Kaakkola
Related services
Despite initial setbacks due to the pandemic, the sector has witnessed a resurgence in mergers and acquisitions, and investments from both private equity and venture capital firms.
Notably, landmark transactions like Novo Nordisk’s USD 16.5 billion acquisition of Catalent and Pfizer’s USD 43 billion merger with Seagen underscore the magnitude and momentum of deal activity within the industry.
Castrén & Snellman’s recent transactional work vividly reflects this heightened industry activity. In 2023 and 2024, our firm has been deeply immersed in facilitating mergers and acquisitions, securing funding and refinancing and supporting manufacturing projects for innovative companies, investors and entrepreneurs in the health tech and life sciences sphere.
Our recent cases showcase Castrén & Snellman’s expertise in navigating complex legal matters within the life sciences and health tech industry:
- Advising Mérieux Equity Partners’ leveraged buyout of Labquality, a Nordic player specialised in EQA, CRO activities and regulatory affairs, with a strong local presence in Central and Eastern Europe
- Advising BYG4Lab and Keensight Capital on BYG4Lab’s acquisition of Finbiosoft, an innovative software company founded in 2011 with a mission to help laboratories reach higher quality and better efficiency
- Advising Keensight Capital, a leading growth buyout investor, on the Finnish legal aspects of the combination of Biovian and 3P Biopharmaceuticals, two leading biologics contract development and manufacturing organisations (CDMOs) backed by Keensight Capital, to establish 3PBIOVIAN, a new pan-European leader in its field
- Advising DigiTx Partners, a venture capital firm specialised in the digital health space, on the USD 10 million series A funding round of CardioSignal, the developer of the first technology to detect major heart diseases without specialised medical hardware
- Advising Inventure, Tesi and Presidio Ventures on the EUR 13.7 million series A funding round of Algorithmiq, a growth company developing quantum computing algorithms and solutions for drug development and discovery
- Advising Biovian, a globally operating GMP (Good Manufacturing Practice) contract development and manufacturing organisation (CDMO) of biopharmaceuticals, on its EUR 50 million manufacturing facility project in Turku, Finland
- Advising Biovian on the debt refinancing initiative and new funding package with Eurazeo to support organic growth and GeneCity facility expansion
- Advising Voisin Consulting Life Sciences on the acquisition of MedEngine, a leading medical science agency in the Nordics.
With favourable economic conditions driving acquisitions, continued interest from private equity and venture capital firms, and the strategic importance of acquisitions for fostering growth, we anticipate continued vibrancy in the industry through the remainder of 2024. In addition, advancements in technology and innovation within the industry are expected to fuel further investment and transactional activity.
Latest insights
Article published 13.5.2026 – Venture Capital & Minority Investments
Newly launched Series Seed 4.0 is a comprehensive standard seed financing documentation for the Finnish market
Article published 28.4.2026 – Private M&A
Unlocking value in carve-outs – Why integration planning deserves top priority in every carve-out
Article published 14.1.2026 – Tax & Structuring
VAT deductions for private equity investors under the microscope
Article published 7.11.2025 – Capital Markets & Public M&A
AIFMD II – implications for alternative investment fund managers in Finland
Jarno Tanhuanpää, Tuomas Honkinen & Jussi Mäkikangas
Benjamin Bade, Maiju Mäkinen & Samuli Salminen
Mikko Alakare & Lotta Manu
Hannu Huotilainen & Freja Harima
Latest references
Jolt Capital and Tesi – Investment in VEV
We advised Jolt Capital and Tesi in connection with their investment in VEV, a leading provider of commercial fleet electrification solutions. The investment, led by Jolt Capital with Tesi as co-investor, will support VEV’s next phase of growth and expansion across Europe. As part of the transaction, VEV became an independent company following the acquisition of Vitol’s stake in the business. Founded by Vitol, VEV provides integrated fleet electrification solutions combining fleet strategy, charging infrastructure, energy supply and operational services. Through its VEV IQ platform, the company supports more than 6,000 commercial electric vehicles across Europe and has been deployed across more than 600 sites spanning the transport, logistics and waste sectors. Jolt Capital is a private equity firm focused on growth investments in European deeptech companies. Tesi is a Finnish state-owned investment company that promotes Finnish business and economic growth through investments. We advised Jolt Capital and Tesi on the equity financing and structuring aspects of the transaction. International law firm Goodwin advised the investors on the acquisition of VEV.
Case published 10.9.2026
Topfoods – Acquisition of Delice Plus
We advised Topfoods Oy, a Triton-backed Geia Group company, on its acquisition of Oy Delice Plus Ab, a Finnish supplier of cakes and pastries. Through the acquisition, Topfoods strengthens its retail business and further reinforces its position in the cakes and pastries segment. Founded in 2008, Topfoods supplies selected food products to professional kitchens, the retail sector, and the food industry.
Case published 4.9.2026
Korona Invest – Sale of Innoflame
We advise Korona Invest and the other shareholders of Innoflame Oy on the sale of Innoflame to Sponsor Capital. The transaction makes Sponsor Capital the new majority owner of Innoflame. Korona Invest has been a shareholder of Innoflame since 2021 and, together with the other selling shareholders, has over the past five years supported the company’s growth, development and several strategically significant corporate transactions, through which Innoflame has strengthened its position as Finland’s leading product media company. The ownership change is intended to support Innoflame’s next phase of growth, including its ambition to build a significant European product media company with the capability to expand rapidly into new markets. The transaction is conditional to the customary closing conditions such as authority approvals. Innoflame is one of Finland’s leading product media specialists, helping its clients build a unified brand experience by offering the design, sourcing and management of product media as a single integrated service. Korona Invest is a Finnish private equity firm founded in 2006, specialising in buyout and growth investments in domestic small and medium-sized enterprises. It makes both majority and minority investments, structuring each project to suit the company’s growth strategy.
Case published 27.8.2026
Ugly Duckling Ventures – EUR 6.5 million funding round of Skyfora
We advised lead investor Ugly Duckling Ventures on the EUR 6.5 million funding round of Skyfora. The round also included Eviny Ventures, LUMO Labs and EIC Fund, alongside non-dilutive funding from Business Finland. The investment will support the commercial scale-up of Skyfora’s weather intelligence solutions, the expansion of partnerships with telecom operators, forecasting providers and meteorological institutions, and the continued growth of the team. Skyfora is a Finnish company developing high-resolution weather data solutions using patented technology that extracts atmospheric data from GNSS receivers embedded in existing infrastructure, such as telecom networks. By unlocking previously untapped data sources, Skyfora enables the next generation of AI-driven weather forecasting and supports improved decision-making across weather-sensitive industries. Ugly Duckling Ventures is a Copenhagen-based venture capital firm focused on early-stage Nordic B2B technology companies, with an emphasis on medtech, resilience tech and business services.
Case published 10.6.2026